Heart and Blood Diseases

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Substance Related Disorders

Wounds and Injuries

Heart Failure

Breast Neoplasms

Cardiotoxicity

Heart Diseases

Antineoplastic Agents

All Drugs and Chemicals

Antihypertensive Agents

Anti-Infective Agents

Trastuzumab

Adrenergic beta-Antagonists

Perindopril

Enzyme Inhibitors

Angiotensin-Converting Enzyme Inhibitors

Bisoprolol

Sympatholytics

Adrenergic Agents

Adrenergic beta-1 Receptor Antagonists

Adrenergic Antagonists

Neurotransmitter Agents

HIV Protease Inhibitors

Protease Inhibitors

perindopril- oral daily titrated does from 2mg up to 8mg

bisoprolol- oral daily titrated dose from 2.5mg up to 10mg

perindopril OR bisoprolol OR placebo

Ian Paterson, MD FRCPC

While trastuzumab has been shown to prevent recurrences of breast cancer, some women may also experience damage to their heart muscle (including heart failure) as a result of their treatment. The investigators hope to learn if standard medications used in heart failure can prevent heart damage caused by trastuzumab in women with breast cancer. The investigators would also like to know if there are any ways to detect this damage earlier using magnetic resonance imaging (MRI) and blood tests.

We propose a randomized, placebo-controlled, double-blind study evaluating the efficacy of an ACE-inhibitor (perindopril) or a beta blocker (bisoprolol) for the prevention of LV remodeling among women with early breast cancer scheduled for chemotherapy and one year of trastuzumab. Participants will undergo cardiac MRI at baseline and 3 and 12 months, replacing the usual MUGA, as well as a post-treatment cardiac MRI at 24 months to evaluate long-term effect.

Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research

A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications

University of Alberta

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research	NCT01016886	Breast Cancer Heart Failure	perindopril OR ...	18 Years -	AHS Cancer Control Alberta
Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research	NCT01016886	Breast Cancer Heart Failure	perindopril OR ...	18 Years -	AHS Cancer Control Alberta

Spots Global Cancer Trial Database for perindopril or bisoprolol or placebo